

## **Loncastuximab Tesirine Market**

Market Report | 2025-05-01 | 260 pages | Datastring Consulting

### **AVAILABLE LICENSES:**

- Multi User License \$4200.00

### **Report description:**

#### Description

The market, for Loncastuximab tesirine was estimated at \$144.7 million in 2024; and it is anticipated to increase to \$252.2 million by 2030 with projections indicating a growth to around \$400.6 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 9.7% over the forecast period.

#### Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

### **Table of Contents:**

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Loncastuximab Tesirine Market Size, Opportunities & Strategic Insights, by Patient Demographics

4.1: Adolescents

4.2: Adults

4.3: Geriatrics

Chapter 5: Global Loncastuximab Tesirine Market Size, Opportunities & Strategic Insights, by Therapeutic Application

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1: Lymphoma
- 5.2: Hematological Disorder
- 5.3: Leukemia
- 5.4: Others

#### Chapter 6: Global Loncastuximab Tesirine Market Size, Opportunities & Strategic Insights, by End User

- 6.1: Hospitals
- 6.2: Specialty Clinics
- 6.3: Cancer Research Institutes
- 6.4: Others

#### Chapter 7: Global Loncastuximab Tesirine Market Size, Opportunities & Strategic Insights, by Distribution Channel

- 7.1: Pharmacies
- 7.2: Online Pharmacies
- 7.3: Direct Supply

#### Chapter 8: Loncastuximab Tesirine Market, by Region

##### 8.1: North America Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.1.1: U.S.
- 8.1.2: Canada

##### 8.2: Europe Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.2.1: Germany
- 8.2.2: France
- 8.2.3: UK
- 8.2.4: Italy
- 8.2.5: The Netherlands
- 8.2.6: Rest of EU

##### 8.3: Asia Pacific Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.3.1: China
- 8.3.2: Japan
- 8.3.3: South Korea
- 8.3.4: India
- 8.3.5: Australia
- 8.3.6: Thailand
- 8.3.7: Rest of APAC

##### 8.4: Middle East & Africa Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.4.1: Saudi Arabia
- 8.4.2: United Arab Emirates
- 8.4.3: South Africa
- 8.4.4: Rest of MEA

##### 8.5: Latin America Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.5.1: Brazil
- 8.5.2: Mexico
- 8.5.3: Rest of LA

##### 8.6: CIS Loncastuximab Tesirine Market Size, Opportunities, Key Trends & Strategic Insights

- 8.6.1: Russia
- 8.6.2: Rest of CIS

#### Chapter 9: Competitive Landscape

- 9.1: Competitive Dashboard & Market Share Analysis
- 9.2: Company Profiles (Overview, Financials, Developments, SWOT)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.1: ADC Therapeutics SA
- 9.2.2: Bayer AG
- 9.2.3: Novartis AG
- 9.2.4: Eli Lilly and Company
- 9.2.5: Biogen Idec
- 9.2.6: Bristol Myers Squibb
- 9.2.7: Teva Pharmaceuticals Industries
- 9.2.8: Amgen Inc.
- 9.2.9: F. Hoffmann-La Roche Ltd.
- 9.2.10: Merck & Co. Inc.
- 9.2.11: AbbVie Inc.
- 9.2.12: Johnson & Johnson.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Loncastuximab Tesirine Market**

Market Report | 2025-05-01 | 260 pages | Datastring Consulting

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Multi User License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com